Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

This strategy has already resulted in the Sanofi partnership we announced this year, which has enabled us to transition away ...

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for ...

Yes, you can get your flu and COVID-19 shots at the same time. Don't call them boosters — they're not just another dose of ...

Novavax, a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, is proud to announce an exciting new partnership with the Los Angeles Rams aimed at "Protecting the Rams House" ...

But COVID-19 tends to jump in the winter months ... The Pfizer and Moderna shots are formulated against a virus subtype ...

On a more positive note, Novavax had said on Monday that its combination vaccine for Covid-19 and influenza was back on track ...